SCHEMBL4075996

SCHEMBL4075996

Cc1cc(C(=O)O)ccc1Nc1ncc2c(n1)N(C1CCCC1)CC(C)C(=O)N2C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 17/20 0.60
PLK3 Q9H4B4 4/20 0.60
PLK2 Q9NYY3 3/20 0.60
BRD4 O60885 11/20 0.53
BRDT Q58F21 11/20 0.53
RAD52 P43351 1/20 0.49
ALK Q9UM73 1/20 0.49
PRKD3 O94806 1/20 0.49
MAP4K4 O95819 1/20 0.49
PRKCG P05129 1/20 0.49
CLK2 P49760 1/20 0.49
RPS6KA3 P51812 1/20 0.49
NEK4 P51957 1/20 0.49
PTK2 Q05397 1/20 0.49
CAMK2G Q13555 1/20 0.49
CAMK2D Q13557 1/20 0.49
SRPK1 Q96SB4 1/20 0.49
PRKD2 Q9BZL6 1/20 0.49
CSNK1G1 Q9HCP0 1/20 0.49
CSNK1G3 Q9Y6M4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2397193 0.90 PLK1 (0.65) PLK1PLK3PLK2BRD4BRDT
SCHEMBL9945372 0.90 PLK1 (0.65) PLK1PLK3PLK2BRD4BRDT
SCHEMBL12825181 0.90 PLK1 (0.65) PLK1PLK3PLK2BRD4BRDT
SCHEMBL4085022 0.89 PLK1 (0.66) PLK1PLK3PLK2BRD4BRDT
SCHEMBL4079129 0.87 PLK1 (0.57) PLK1PLK3PLK2BRD4BRDT
SCHEMBL4078301 0.86 PLK1 (0.67) PLK1PLK3PLK2BRD4BRDT
SCHEMBL4085905 0.86 PLK1 (0.58) PLK1PLK3PLK2BRD4BRDT
SCHEMBL861945 0.85 PLK1 (0.70) PLK1PLK3PLK2BRD4BRDT
SCHEMBL21527106 0.85 PLK1 (0.70) PLK1PLK3PLK2BRD4BRDT
SCHEMBL1204391 0.85 PLK1 (0.67) PLK1PLK3PLK2BRD4BRDT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7517873-B2 Substituted pyrimidodiazepines HOFFMAN-LA ROCHE INC. (US) 2009-04-14 US disclosed
US-7517873-B2 Substituted pyrimidodiazepines HOFFMAN-LA ROCHE INC. (US) 2009-04-14 US disclosed
US-7517873-B2 Substituted pyrimidodiazepines HOFFMAN-LA ROCHE INC. (US) 2009-04-14 US disclosed
US-20080234255-A1 SUBSTITUTED PYRIMIDODIAZEPINES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-25 US disclosed
US-20080234255-A1 SUBSTITUTED PYRIMIDODIAZEPINES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-25 US disclosed
US-20080234255-A1 SUBSTITUTED PYRIMIDODIAZEPINES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234255-A1 SUBSTITUTED PYRIMIDODIAZEPINES PLK1, CCNI, CDK1 PLK1 1/4885PLK3 17/4885PLK2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.